Sep 21, 2020
Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 1: Biomarker assessment in metastatic NSCLC: Predictors of response to targeted therapy and immunotherapy — Dr Govindan. CME information and select publications
Sep 21, 2020
Striving for Consensus on the Optimal Management of Metastatic
Non-Small Cell Lung Cancer — Faculty Presentation 2: First-line
treatment for patients with metastatic NSCLC without a targetable
tumor mutation — Dr Horn.
CME information and select...
Sep 21, 2020
Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 3: Second- and later-line treatment for patients with metastatic NSCLC without a targetable tumor mutation who have experienced disease progression on a checkpoint inhibitor alone or combined with...
Sep 21, 2020
Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 4: Anti-angiogenic agents in NSCLC: Where we are, where we are going — Dr Heymach. CME information and select publications
Sep 21, 2020
Striving for Consensus on the Optimal Management of Metastatic
Non-Small Cell Lung Cancer — Faculty Presentation 6: Management of
metastatic NSCLC in special populations — Dr Levy.
CME information and select publications